10q10k10q10k.net
Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp.KTTAEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

Pasithea Therapeutics Corp. is a clinical-stage biopharmaceutical firm dedicated to developing novel treatments for psychiatric and neurological conditions including treatment-resistant mood disorders. It primarily operates in North American and European markets, targeting patient segments that lack effective existing treatment options.

Q4 2022Q3 2022Q2 2022Q1 2022

Revenue

$13.6K

Gross Profit

N/A

Operating Profit

$-2.6M

Net Profit

$-2.7M

Gross Margin

N/A

Operating Margin

-19229.5%

Net Margin

-19574.4%

YoY Growth

N/A

EPS

$-0.02

Pasithea Therapeutics Corp. Q2 FY2022 Financial Summary

Pasithea Therapeutics Corp. reported revenue of $13.6K for Q2 FY2022, with a net profit of $-2.7M (-19574.4% margin).

Key Financial Metrics

Total Revenue$13.6K
Net Profit$-2.7M
Gross MarginN/A
Operating Margin-19229.5%
Report PeriodQ2 FY2022

Pasithea Therapeutics Corp. Annual Revenue by Year

Pasithea Therapeutics Corp. annual revenue history includes year-by-year totals (for example, 2022 revenue was $486.6K).

YearAnnual Revenue
2022$486.6K

Pasithea Therapeutics Corp. Quarterly Revenue & Net Profit History

Pasithea Therapeutics Corp. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q4 FY2022$240.7K—$-5.1M-2126.1%
Q3 FY2022$218.6K+43133.1%$-4.6M-2097.9%
Q2 FY2022$13.6K—$-2.7M-19574.4%
Q1 FY2022$13.7K—$-1.6M-11526.1%

Income Statement

Q1 2022Q2 2022Q3 2022Q4 2022
Revenue$13658$13581$218608$240712
YoY GrowthN/AN/A43133.1%N/A

Balance Sheet

Q1 2022Q2 2022Q3 2022Q4 2022
Assets$51.1M$53.0M$49.6M$45.2M
Liabilities$1.1M$1.6M$2.8M$2.7M
Equity$50.0M$51.3M$46.8M$42.5M

Cash Flow

Q1 2022Q2 2022Q3 2022Q4 2022
Operating CF$-2.5M$-2.4M$-5.2M$-4.4M